Results 41 to 50 of about 231,111 (314)

Cellular and vaccine therapeutic approaches for gliomas

Journal of Translational Medicine, 2010
Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prognosis for patients with this disease is still poor.
Liau Linda M, Prins Robert M, Jadus Martin R, Erickson Kate L, Malone Colin C, Hickey Michelle J, Kruse Carol A   +6 more
doaj   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Journal for ImmunoTherapy of Cancer, 2023
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza   +22 more
doaj   +1 more source

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]

, 2017
Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe, Awada, Ahmad, Brayer, Jason B, Catala, Gaetan, Davila, Marco L, Gilham, David E, Hendlisz, Alain, Kerre, Tessa, Lehmann, Frederic F, Lonez, Caroline, Machiels, Jean-Pascal H, Odunsi, Kunle, Piette, Fanny, Sallman, David A, Van den Neste, Eric, Verma, Bikash   +15 more
core   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy

Frontiers in Immunology, 2023
Immunotherapy is a type of treatment that uses our own immune system to fight cancer. Studies have shown that traditional Chinese medicine (TCM) has antitumor activity and can enhance host immunity. This article briefly describes the immunomodulatory and
Chao Yang, Dan Li, Chung-Nga Ko, Kai Wang, Haiyong Wang   +4 more
doaj   +1 more source

Pancreas, Muscle, and Subcutaneous Fat Atrophy in Patients Undergoing Radiation for Neuroblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Radiation therapy (RT) is part of standard‐of‐care therapy in high‐risk neuroblastoma (HR‐NBL) but can significantly affect nearby tissue. The objectives of this study were (1) to characterize changes in pancreas volume after RT and (2) to characterize changes in body composition, including body weight percentile ...
Pradipta Debnath, Marissa Ray, Luke Pater, Alexandra O. Glenn, Stephen Hartman, Elanchezhian Somasundaram, Todd Jenkins, Juan P. Gurria, Katherine Somers, Andrew T. Trout, Meera Kotagal   +10 more
wiley   +1 more source

Immunotherapy in hematologic malignancies: past, present, and future

Journal of Hematology & Oncology, 2017
The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid ...
Annie Im, Steven Z. Pavletic
doaj   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source